Successful use of ivermectin in the treatment of endemic scabies in a nursing home.
Ivermectin, an antiparasitic agent, was successfully used as a sole agent to combat endemic scabies in a closed 33-bed ward of a rural nursing home. Previous topical therapies, including multiple applications of permethrin, gamma-benzene hexachloride, benzyl benzoate and precipitated sulfur in white soft paraffin, had failed. Several patients exhibited hyperkeratotic crusted scabies with head and neck involvement and all residents except one recently arrived resident had evidence of active infestation. All residents were treated with 200 micrograms/kg of ivermectin and this dose was repeated 2 weeks later in all subjects. Four weeks after the first dose of ivermectin there was no evidence of active scabies and all rashes were totally resolved by 6 weeks. The action of ivermectin, its safety and its indications are discussed.
Sullivan
J R
JR
Department of Dermatology, Royal Newcastle Hospital, New South Wales, Australia.
Watt
G
G
Barker
B
B
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D001315:Australia; D019353:Endemic Diseases / Q000517:prevention & control*; D006707:Homes for the Aged; D006801:Humans; D007306:Insecticides / Q000627:therapeutic use*; D007559:Ivermectin / Q000627:therapeutic use*; D008297:Male; D009735:Nursing Homes; D012532:Scabies / Q000188:drug therapy* / Q000453:epidemiology; D016896:Treatment Outcome
D007306:Insecticides; D007559:Ivermectin